View source for 20240010980. NATURAL KILLER CELLS WITH ENHANCED ACTIVITY simplified abstract (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)

=NATURAL KILLER CELLS WITH ENHANCED ACTIVITY=


==Organization Name==

[[:Category:THE REGENTS OF THE UNIVERSITY OF CALIFORNIA|THE REGENTS OF THE UNIVERSITY OF CALIFORNIA]]


[[Category:THE REGENTS OF THE UNIVERSITY OF CALIFORNIA]]

==Inventor(s)==

[[:Category:Dan S. Kaufman of La Jolla CA (US)|Dan S. Kaufman of La Jolla CA (US)]][[Category:Dan S. Kaufman of La Jolla CA (US)]]

[[:Category:Kenta Yamamoto of La Jolla CA (US)|Kenta Yamamoto of La Jolla CA (US)]][[Category:Kenta Yamamoto of La Jolla CA (US)]]

==NATURAL KILLER CELLS WITH ENHANCED ACTIVITY - A simplified explanation of the abstract==


This abstract first appeared for US patent application 20240010980 titled 'NATURAL KILLER CELLS WITH ENHANCED ACTIVITY

==Simplified Explanation==

The abstract of the patent application describes the invention of engineered immune cells, specifically natural killer (NK) cells, that have an inactivating mutation for a gene called a-disintegrin-and-metalloproteinase 17 (ADAM 17). These ADAM17-deficient immune cells are produced from stem cells, including induced pluripotent stem cells (iPSCs), and have enhanced antibody-dependent cellular cytotoxicity (ADCC). The patent application also includes pharmaceutical compositions comprising these engineered immune cells, as well as methods for making and using them.

* Engineered immune cells, particularly NK cells, are created with an inactivating mutation in the ADAM 17 gene.
* The ADAM17-deficient immune cells are derived from stem cells, including iPSCs.
* The engineered immune cells exhibit enhanced ADCC, which is the ability to kill target cells using antibodies.
* Pharmaceutical compositions containing these engineered immune cells are disclosed.
* Methods for producing the engineered immune cells and pharmaceutical compositions are provided.
* The invention has potential applications in immunotherapy and cancer treatment.
* The technology solves the problem of limited efficacy of immune cells in killing target cells.
* The engineered immune cells overcome the limitations of endogenous ADAM 17 activity, leading to enhanced ADCC.
* The benefits of this technology include improved immune cell function and potential for more effective cancer treatments.


==Original Abstract Submitted==

engineered immune cells, optionally natural killer (nk) cells, comprising an inactivating mutation for an endogenous a-disintegrin-and-metalloproteinase 17 (adam 17) gene. adam17-deficient immune cells produced from stem cells, optionally, induced pluripotent stem cells (ipscs), having enhanced antibody-dependent cellular cytotoxicity (adcc). pharmaceutical compositions comprising said engineered immune cells. methods for making the engineered immune cell and pharmaceutical compositions, and methods of use are provided.



[[Category:C12N5/0783]]
[[Category:C12N9/64]]
[[Category:A61K35/17]]
[[Category:C07K16/28]]
[[Category:A61P35/00]]
[[Category:A61K35/545]]